Apple Tree Partners II

Red Queen Therapeutics is a biotechnology company engaged in the development of innovative solutions across multiple sectors, including medicine and agriculture. The company focuses on creating biotechnology drugs designed to provide rapid responses to current and emerging pathogens that pose risks to human health. Utilizing a unique plug-and-play antiviral platform based on stapled peptide decoys, Red Queen Therapeutics aims to swiftly address both pandemic and pandemic-potential viruses, as well as other viruses responsible for recurring diseases. Through its research and development efforts, the company seeks to produce a range of commercial products that address critical health challenges and enhance protection against infections.

Deep Apple Therapeutics is a biotechnology research company dedicated to enhancing drug discovery through innovative methodologies. By integrating advanced computer-aided drug design technologies with expertise in molecular docking and structural biology, Deep Apple aims to streamline the development of small-molecule therapeutics. The company is focused on accelerating the drug discovery process, allowing clients to efficiently create a foundation for new therapeutic solutions. With a commitment to speed and precision, Deep Apple leverages its capabilities to drive advancements in healthcare and improve patient outcomes.

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.

Aulos Bioscience is a biotechnology company focused on transforming cancer treatment through innovative immuno-oncology therapeutics. The company aims to enhance patient care by developing targeted antibodies that direct the immune system to effectively eliminate tumor cells. Their approach emphasizes precision in targeting solid tumors, allowing healthcare providers to deliver more effective therapies. By concentrating on this niche within cancer treatment, Aulos Bioscience seeks to provide advanced solutions that can significantly improve patient outcomes.

Initial Therapeutics is a biotechnology company focused on the development of small-molecule medicines aimed at preventing pathogenic protein synthesis. Unlike traditional methods that target fully formed proteins, the company’s innovative approach allows for intervention at an earlier stage, addressing difficult-to-drug targets in areas with significant unmet medical needs. By emphasizing this preemptive strategy, Initial Therapeutics seeks to offer effective solutions for challenging medical conditions.

Aethon Therapeutics is focused on advancing cancer treatment through a novel approach that combines immunotherapy with targeted therapies. The company develops unique anti-drug-peptide conjugate/MHC antibodies that work in conjunction with targeted covalent inhibitors aimed at oncogenic mutations such as RAS and EGFR. This innovative platform is designed to create neoantigens by design, enhancing the immune system's ability to selectively attack and eliminate residual cancer cells, including those that are drug-resistant. By integrating these technologies, Aethon Therapeutics aims to transform cancer treatments into potential cures, offering new hope for patients facing challenging forms of the disease.

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.

Galvanize Therapeutics is a medical technology company specializing in energy-based devices aimed at improving biological processes for therapeutic applications. Founded in 2022 by Apple Tree Partners, the company focuses on developing innovative solutions to treat various medical conditions, including chronic bronchitis, cardiac arrhythmias, and solid tumors. Its platform employs short-duration, high-voltage electrical pulses to create electric fields that destabilize cells through multiple biochemical mechanisms. This technology enhances the ability of medical professionals to provide effective healthcare services, positioning Galvanize Therapeutics as a potential leader in delivering cutting-edge medical innovations.

Adendra Therapeutics is an emerging biotechnology company focused on leveraging advancements in dendritic cell biology to discover and develop innovative small molecule and biologic medicines. The company specializes in creating therapeutics aimed at treating various cancers and autoimmune diseases by harnessing the unique properties of dendritic cells, particularly their capability to cross-present antigens. Through this approach, Adendra seeks to contribute to the healthcare sector by providing effective solutions for cancer treatment and enhancing immune responses against autoimmune disorders.

Marengo Therapeutics is a biopharmaceutical company focused on developing immune activation therapeutics aimed at treating cancer. The company specializes in the creation of antibodies that induce targeted and durable anti-tumor responses in malignant solid tumor models. These therapies promote protective tumor immunity and stimulate cytokine release, which enhances the expansion of an antigen-specific memory T cell repertoire. By addressing challenging and life-threatening diseases, Marengo Therapeutics aims to improve treatment outcomes for patients and make a significant positive impact on their lives.

Intergalactic Therapeutics is a biotechnology company focused on transforming gene therapies through its innovative non-viral platform. The company specializes in the development of covalently closed and circular DNA (C3DNA) molecules, which address the limitations commonly associated with viral-based gene therapies. By utilizing synthetic biology and engineered gene circuits, Intergalactic Therapeutics aims to enhance the safety and accessibility of genetic medicine. Its lead delivery technology, the COMET® pulsed electric field system, facilitates targeted therapeutic delivery. The company is advancing programs in various therapeutic areas, including ophthalmology, oncology, respiratory diseases, and is exploring applications in central nervous system, renal, and musculoskeletal disorders. Through its proprietary cell-free manufacturing process, Intergalactic Therapeutics is dedicated to making gene therapy solutions safer and more effective for patients.

Replicate Bioscience is focused on developing innovative oncology treatments that aim to prevent and reverse drug resistance in cancer therapies. Utilizing a self-replicating RNA platform known as SynRGY, the company designs novel treatments that enhance the effectiveness of immuno-oncology regimens. By leveraging synthetic biology approaches, Replicate Bioscience seeks to revolutionize cancer treatment by not only addressing drug resistance but also improving the detection and elimination of cancerous cells, thereby providing healthcare professionals with advanced therapeutic options.

Galaxy Medical is a privately held medical device company focused on developing innovative technologies for the treatment of cardiac arrhythmia. The company's flagship device employs pulsed electric field technology, which utilizes high voltage, high-frequency bursts of electro-surgical energy to ablate tissue. This advanced approach allows electrophysiologists to perform safe and effective ablation procedures tailored to the needs of patients, ultimately enhancing medical outcomes.

Replicate Bioscience is focused on developing innovative oncology treatments that aim to prevent and reverse drug resistance in cancer therapies. Utilizing a self-replicating RNA platform known as SynRGY, the company designs novel treatments that enhance the effectiveness of immuno-oncology regimens. By leveraging synthetic biology approaches, Replicate Bioscience seeks to revolutionize cancer treatment by not only addressing drug resistance but also improving the detection and elimination of cancerous cells, thereby providing healthcare professionals with advanced therapeutic options.

Aulos Bioscience is a biotechnology company focused on transforming cancer treatment through innovative immuno-oncology therapeutics. The company aims to enhance patient care by developing targeted antibodies that direct the immune system to effectively eliminate tumor cells. Their approach emphasizes precision in targeting solid tumors, allowing healthcare providers to deliver more effective therapies. By concentrating on this niche within cancer treatment, Aulos Bioscience seeks to provide advanced solutions that can significantly improve patient outcomes.

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.

Intergalactic Therapeutics is a biotechnology company focused on transforming gene therapies through its innovative non-viral platform. The company specializes in the development of covalently closed and circular DNA (C3DNA) molecules, which address the limitations commonly associated with viral-based gene therapies. By utilizing synthetic biology and engineered gene circuits, Intergalactic Therapeutics aims to enhance the safety and accessibility of genetic medicine. Its lead delivery technology, the COMET® pulsed electric field system, facilitates targeted therapeutic delivery. The company is advancing programs in various therapeutic areas, including ophthalmology, oncology, respiratory diseases, and is exploring applications in central nervous system, renal, and musculoskeletal disorders. Through its proprietary cell-free manufacturing process, Intergalactic Therapeutics is dedicated to making gene therapy solutions safer and more effective for patients.

Marengo Therapeutics is a biopharmaceutical company focused on developing immune activation therapeutics aimed at treating cancer. The company specializes in the creation of antibodies that induce targeted and durable anti-tumor responses in malignant solid tumor models. These therapies promote protective tumor immunity and stimulate cytokine release, which enhances the expansion of an antigen-specific memory T cell repertoire. By addressing challenging and life-threatening diseases, Marengo Therapeutics aims to improve treatment outcomes for patients and make a significant positive impact on their lives.

Nereid Therapeutics, headquartered in Cambridge, Massachusetts, specializes in the discovery of small molecule therapeutics targeting protein interactions involved in diseases, utilizing its proprietary technology focused on liquid-liquid phase separation and biomolecular condensate formation.

Galaxy Medical is a privately held medical device company focused on developing innovative technologies for the treatment of cardiac arrhythmia. The company's flagship device employs pulsed electric field technology, which utilizes high voltage, high-frequency bursts of electro-surgical energy to ablate tissue. This advanced approach allows electrophysiologists to perform safe and effective ablation procedures tailored to the needs of patients, ultimately enhancing medical outcomes.

Initial Therapeutics is a biotechnology company focused on the development of small-molecule medicines aimed at preventing pathogenic protein synthesis. Unlike traditional methods that target fully formed proteins, the company’s innovative approach allows for intervention at an earlier stage, addressing difficult-to-drug targets in areas with significant unmet medical needs. By emphasizing this preemptive strategy, Initial Therapeutics seeks to offer effective solutions for challenging medical conditions.

Nine Square Therapeutics is engaged in the development of small-molecule therapeutics aimed at treating degenerative movement disorders, including Parkinson's disease and amyotrophic lateral sclerosis (ALS), as well as non-degenerative conditions such as essential tremor and dyskinesias. Founded in 2020 and based in New York, the company employs an innovative approach that combines computational chemistry, biophysics, and computational biology with machine-learning-enabled cell profiling platforms. This methodology enhances the processes of target identification, chemical optimization, and patient stratification, enabling healthcare professionals to more effectively address the challenges posed by these movement disorders.

Gala Therapeutics is a privately-held medical device company based in Menlo Park, California, that specializes in developing disease-modifying therapies aimed at improving survival and quality of life for patients suffering from pulmonary diseases, including lung cancer, chronic obstructive pulmonary disease (COPD), and asthma. Founded in 2015, the company's innovative platform includes a single-use catheter and an electrosurgical generator that deliver non-thermal energy to the airways, effectively reducing mucus-producing cells. This technology provides interventional pulmonologists, thoracic surgeons, and other healthcare providers with enhanced tools to treat their patients, ultimately resulting in better medical outcomes.

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, that specializes in the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational endothelin receptor antagonist currently prepared for Phase III trials targeting IgA nephropathy and other primary glomerular diseases. In addition to atrasentan, Chinook is developing BION-1301, an investigational anti-APRIL monoclonal antibody evaluated in a Phase Ib trial for IgA nephropathy, and CHK-336, a preclinical candidate aimed at treating an undisclosed ultra-orphan kidney disease. Chinook Therapeutics is also engaged in research programs addressing other rare and severe chronic kidney conditions, including polycystic kidney disease.

Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.

Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing novel antisense oligonucleotide medicines aimed at addressing the underlying causes of severe genetic diseases. Founded in 2014 and headquartered in Bedford, Massachusetts, the company utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach to enhance gene expression through RNA splicing. Its lead product candidate, STK-001, is currently in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics has also partnered with Invitae Corporation to offer complementary genetic testing services.

Akero Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, founded in 2017. The company is dedicated to the development and commercialization of innovative treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage that can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate aims to address the underlying mechanisms of NASH by reducing liver fat and suppressing inflammation and fibrosis. With a focus on providing effective treatment options for conditions lacking approved therapies, Akero Therapeutics seeks to restore metabolic balance and improve patient outcomes in metabolic disease management.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

Braeburn Inc. is a pharmaceutical company focused on developing and commercializing treatments for serious central nervous system disorders, with a primary emphasis on opioid addiction. Founded in 2012 and headquartered in Plymouth Meeting, Pennsylvania, Braeburn aims to provide innovative solutions for individuals affected by opioid use disorder (OUD). The company's lead product candidate, BRIXADI, is an extended-release injectable formulation of buprenorphine designed for the treatment of moderate to severe OUD. Braeburn is committed to advancing next-generation therapies that offer individualized dosing regimens and delivery options, striving to improve care for patients and address the growing challenges associated with addiction.

Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing novel antisense oligonucleotide medicines aimed at addressing the underlying causes of severe genetic diseases. Founded in 2014 and headquartered in Bedford, Massachusetts, the company utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach to enhance gene expression through RNA splicing. Its lead product candidate, STK-001, is currently in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics has also partnered with Invitae Corporation to offer complementary genetic testing services.

Elstar Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on the development of immunotherapies. Established in 2015, Elstar Therapeutics specializes in creating antibody-based, multi-functional therapeutics aimed at treating various diseases, particularly in the fields of oncology and autoimmunity. The company is dedicated to advancing precision cancer immunotherapy through innovative approaches to molecule generation.

Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, the company leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to create novel therapies that address IgG-mediated autoimmune conditions. Syntimmune aims to transform treatment options by developing humanized monoclonal antibodies that inhibit the interaction between FcRn and immunoglobulin G (IgG) and IgG immune complexes, thereby improving patient outcomes in rare autoimmune diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, the company leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to create novel therapies that address IgG-mediated autoimmune conditions. Syntimmune aims to transform treatment options by developing humanized monoclonal antibodies that inhibit the interaction between FcRn and immunoglobulin G (IgG) and IgG immune complexes, thereby improving patient outcomes in rare autoimmune diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.

ROX Medical, Inc. is a medical device company based in San Clemente, California, that specializes in developing interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). Founded in 2003, the company has introduced the ROX Coupler, a device designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, this device aims to improve respiratory function in COPD patients by facilitating better oxygen delivery to tissues, thus alleviating symptoms and enhancing exercise tolerance. ROX Medical is focused on delivering innovative solutions to improve patient outcomes in both hypertension and respiratory health.

VytronUS, Inc. is a manufacturer of cardiac medical devices, specializing in solutions for treating cardiac arrhythmia. Founded in 2006 and based in Sunnyvale, California, the company develops innovative technologies that leverage ultrasound energy for both imaging and therapeutic purposes. Its devices facilitate precise, non-contact energy delivery and create high-resolution maps of cardiac anatomy, empowering physicians to address complex arrhythmias with enhanced visualization and precision. VytronUS's focus on automation and flexibility in its device offerings positions it as a key player in the cardiac medical device market.

Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, the company leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to create novel therapies that address IgG-mediated autoimmune conditions. Syntimmune aims to transform treatment options by developing humanized monoclonal antibodies that inhibit the interaction between FcRn and immunoglobulin G (IgG) and IgG immune complexes, thereby improving patient outcomes in rare autoimmune diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

QualDerm Partners specializes in offering strategic leadership and practice management services to dermatologists and skin care professionals throughout the southeastern United States. By focusing on a practice-centric philosophy, QualDerm enables healthcare providers to prioritize patient care while minimizing administrative burdens. The company provides essential management support, capital, and guidance, facilitating sustainable growth and profitability for dermatological practices. This approach allows physicians to concentrate on delivering quality care while efficiently managing the operational and administrative aspects of their practices.

Cure Forward Corp. is a healthcare company focused on genomic medicine, consumer healthcare, oncology, and clinical trials, headquartered in Cambridge, Massachusetts. Established in 2012, the company has developed an online portal that facilitates access to genomic testing data for patients and doctors. This platform allows cancer patients and their families to share medical test results, engage with healthcare providers, and discover relevant treatment options, including clinical trials. By connecting patients to advanced oncology treatments and fostering a supportive community, Cure Forward aims to enhance the patient experience and improve outcomes in cancer care.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

VytronUS, Inc. is a manufacturer of cardiac medical devices, specializing in solutions for treating cardiac arrhythmia. Founded in 2006 and based in Sunnyvale, California, the company develops innovative technologies that leverage ultrasound energy for both imaging and therapeutic purposes. Its devices facilitate precise, non-contact energy delivery and create high-resolution maps of cardiac anatomy, empowering physicians to address complex arrhythmias with enhanced visualization and precision. VytronUS's focus on automation and flexibility in its device offerings positions it as a key player in the cardiac medical device market.

Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, the company leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to create novel therapies that address IgG-mediated autoimmune conditions. Syntimmune aims to transform treatment options by developing humanized monoclonal antibodies that inhibit the interaction between FcRn and immunoglobulin G (IgG) and IgG immune complexes, thereby improving patient outcomes in rare autoimmune diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

Cerecor Inc. is a biopharmaceutical company dedicated to the development and commercialization of treatments for rare pediatric and orphan diseases. Founded in 2011 and headquartered in Rockville, Maryland, the company is advancing a clinical-stage pipeline that includes therapies for inherited metabolic disorders, such as CERC-801, CERC-802, and CERC-803, which are focused on congenital disorders of glycosylation. Additionally, Cerecor is developing CERC-006, an oral mTOR inhibitor aimed at treating complex lymphatic malformations, and two monoclonal antibodies: CERC-002, targeting the cytokine LIGHT for severe pediatric-onset Crohn's disease, and CERC-007, targeting IL-18 for autoimmune inflammatory diseases like adult onset Still's disease and multiple myeloma. Several of these therapies have received Orphan Drug Designation and Rare Pediatric Disease Designation, qualifying them for expedited review upon FDA approval. Cerecor also offers Millipred, an oral prednisolone for various inflammatory conditions.

Tendyne Holdings Inc. is a clinical stage medical device company based in Roseville, Minnesota, and was incorporated in 2010. The company specializes in the development of innovative minimally invasive therapies for mitral regurgitation, a condition affecting numerous individuals globally. Tendyne Holdings focuses on creating a transcatheter mitral valve replacement prosthesis designed to treat this affliction. The valve is engineered to be deployed and secured without disrupting the native mitral annulus, while preserving the sub-valvular apparatus. The placement procedure is intended to be simple and performed transapically, allowing the implanting physician to reposition, remove, and re-deploy the valve as necessary during the intervention. In August 2015, Tendyne Holdings became a subsidiary of Abbott Laboratories.

Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company headquartered in Victoria, Canada, focused on developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily engaged in the development of voclosporin, an investigational drug aimed at treating lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia's efforts are concentrated on targeted patient populations in the United States and China, where it seeks to provide innovative solutions for conditions that currently lack effective treatments.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing and advancing clinical-stage oncology drug candidates. Owned by Celgene, the company specializes in hematological malignancies and is best known for its lead compound, romidepsin. This late-stage oncology drug is a histone deacetylase (HDAC) inhibitor that has demonstrated potential efficacy in treating various forms of T-cell lymphomas and other hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester Pharmaceuticals retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of multiple HDAC classes in preclinical studies. The company aims to progress its drug candidates through regulatory approval and commercialization to address unmet medical needs in oncology.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing and advancing clinical-stage oncology drug candidates. Owned by Celgene, the company specializes in hematological malignancies and is best known for its lead compound, romidepsin. This late-stage oncology drug is a histone deacetylase (HDAC) inhibitor that has demonstrated potential efficacy in treating various forms of T-cell lymphomas and other hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester Pharmaceuticals retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of multiple HDAC classes in preclinical studies. The company aims to progress its drug candidates through regulatory approval and commercialization to address unmet medical needs in oncology.

Cyrano Sciences, is focused on providing chemical and biological sensors and software solutions.